XML 73 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Comprehensive Income (Loss) (USD $)
In Thousands, except Share data, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Consolidated Statements of Comprehensive Income (Loss)      
Sales (note 21) $ 72,524 $ 49,216 $ 56,842
Cost of sales 21,273 19,100 21,128
Gross profit 51,251 30,116 35,714
Selling, general and administrative expenses(including rent expenses incurred to related party of 2011 - $805, 2012 - $823, 2013 - $847) (note 12(b)) 34,538 33,280 23,809
Recovery for doubtful accounts (504) (874) (167)
Research and development expenses - (net of 2011- $686, 2012- $125, 2013- $nil in government research grants) 8,384 17,044 9,007
Loss on disposal and impairment of property, plant and equipment(note 6) 88 2,190 455
Government grants recognised in income   (373) (764)
Total operating expenses 42,506 51,267 32,340
Operating income (loss) 8,745 (21,151) 3,374
Interest and financing expenses - (net of 2011-$596; 2012-$1,458; 2013- $65 in interest subsidies) (3,031) (775) (384)
Interest income 2,168 2,370 1,397
Other income (expenses) 263 (77) 280
Income (loss)before income taxes and non-controlling interests 8,145 (19,633) 4,667
Income tax benefit (expense) (note 10) 2,225 884 (5,066)
Net income(loss) 10,370 (18,749) (399)
Less: (income) loss attributable to non-controlling interests (2,928) 3,896 (445)
Net income (loss) attributable to stockholders of Sinovac 7,442 (14,853) (844)
Other comprehensive income(loss), net of tax of nil      
Foreign currency translation adjustments 2,686 2,024 3,639
Total comprehensive income (loss) 13,056 (16,725) 3,240
Less: comprehensive (income) loss attributable to non-controlling interests (3,244) 3,665 (973)
Comprehensive income (loss) attributable to stockholders of Sinovac $ 9,812 $ (13,060) $ 2,267
Basic and diluted earnings(loss) per share (note 20) (in dollars per share) $ 0.13 $ (0.27) $ (0.02)
Weighted average number of shares of common stock outstanding      
- Basic (in shares) 55,301,276 54,926,440 54,608,919
- Diluted (in shares) 55,802,338 54,926,440 54,608,919